Skip to main content

Vibegron News

Sumitomo Pharma America Announces U.S. FDA Approval of Gemtesa (vibegron) for Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic Hyperplasia

MARLBOROUGH, Mass., Dec. 23, 2024 /PRNewswire/ – Sumitomo Pharma America, Inc. (SMPA) announced today that the U.S. Food and Drug Administration (FDA) has approved Gemtesa (vibegron), a beta-3 (β3) ...

FDA Approves Gemtesa (vibegron) Tablets for the Treatment of Patients with Overactive Bladder (OAB)

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Dec. 23, 2020-- Urovant Sciences (Nasdaq: UROV) announced today that the U.S. Food and Drug Administration (FDA) has approved the New Drug...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Overactive Bladder

Related drug support groups

Gemtesa

Vibegron patient information at Drugs.com